NO333254B1 - Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. - Google Patents
Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom.Info
- Publication number
- NO333254B1 NO333254B1 NO20051426A NO20051426A NO333254B1 NO 333254 B1 NO333254 B1 NO 333254B1 NO 20051426 A NO20051426 A NO 20051426A NO 20051426 A NO20051426 A NO 20051426A NO 333254 B1 NO333254 B1 NO 333254B1
- Authority
- NO
- Norway
- Prior art keywords
- clusterin
- melanoma
- composition
- treatment
- subject
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title 1
- 230000009368 gene silencing by RNA Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000003780 Clusterin Human genes 0.000 abstract 6
- 108090000197 Clusterin Proteins 0.000 abstract 6
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108091007065 BIRCs Proteins 0.000 abstract 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40519302P | 2002-08-21 | 2002-08-21 | |
| US40815202P | 2002-09-03 | 2002-09-03 | |
| US31974802P | 2002-12-02 | 2002-12-02 | |
| US47238703P | 2003-05-20 | 2003-05-20 | |
| PCT/CA2003/001276 WO2004018675A1 (en) | 2002-08-21 | 2003-08-21 | Treatment of melanoma by reduction in clusterin levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20051426L NO20051426L (no) | 2005-05-12 |
| NO333254B1 true NO333254B1 (no) | 2013-04-22 |
Family
ID=31950766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051426A NO333254B1 (no) | 2002-08-21 | 2005-03-17 | Anvendelse av en sammensetning som omfatter et antisens oligodeoxynukleotid eller et RNA interferens-induserende molekyl for fremstilling av en farmasoytisksammensetning for behandling av melanom. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7285541B2 (https=) |
| EP (1) | EP1530636B1 (https=) |
| JP (1) | JP4620585B2 (https=) |
| KR (1) | KR101052289B1 (https=) |
| AT (1) | ATE478142T1 (https=) |
| AU (1) | AU2003258425B2 (https=) |
| CA (1) | CA2494764C (https=) |
| CY (1) | CY1110936T1 (https=) |
| DE (1) | DE60333839D1 (https=) |
| DK (1) | DK1530636T3 (https=) |
| IL (1) | IL166657A (https=) |
| NO (1) | NO333254B1 (https=) |
| NZ (1) | NZ538288A (https=) |
| PT (1) | PT1530636E (https=) |
| SI (1) | SI1530636T1 (https=) |
| WO (1) | WO2004018675A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100768109B1 (ko) | 1999-02-26 | 2007-10-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| AU2003237616B2 (en) | 2002-01-17 | 2007-07-05 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| NZ538288A (en) | 2002-08-21 | 2008-04-30 | Univ British Columbia | Treatment of melanoma by reduction in clusterin levels |
| JP4717633B2 (ja) | 2002-08-21 | 2011-07-06 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| BRPI0508970A (pt) * | 2004-03-19 | 2007-08-21 | Penn State Res Found | método combinatórios e composições para o tratamento de melanoma |
| WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
| DK1814595T3 (da) * | 2004-11-23 | 2014-03-31 | Univ British Columbia | Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne |
| AU2006291990B2 (en) * | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| BRPI0616370A2 (pt) * | 2005-09-19 | 2011-06-14 | Johnson & Johnson Pharmaceutical Res & Dev L L C | modulaÇço da expressço de receptor de glucocorticàide |
| WO2009028968A1 (en) * | 2007-08-28 | 2009-03-05 | Auckland Uniservices Limited | Cell marker of melanocyte cell lineage and uses thereof |
| CN102666585B (zh) | 2009-11-24 | 2015-02-18 | 阿莱斯亚生物疗法股份有限公司 | 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途 |
| WO2012123823A1 (en) | 2011-03-15 | 2012-09-20 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| JP2015501155A (ja) | 2011-10-25 | 2015-01-15 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｇｃｃｒ発現のアンチセンス調整 |
| WO2013123588A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| US9937161B2 (en) | 2013-03-06 | 2018-04-10 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| CA2900533A1 (en) * | 2013-03-14 | 2014-10-02 | Oncogenex Technologies Inc. | Anti-clusterin monotherapy for cancer treatment |
| WO2023147417A2 (en) * | 2022-01-26 | 2023-08-03 | Idexx Laboratories, Inc. | Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6111094A (en) * | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| ATE356630T1 (de) * | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6464975B2 (en) | 1998-12-11 | 2002-10-15 | The Research Foundation Of State University Of New York | Compositions and methods for altering cell migration |
| KR100768109B1 (ko) * | 1999-02-26 | 2007-10-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| MXPA02006167A (es) | 1999-12-21 | 2004-02-26 | Univ Yale | Promocion de la angiogenesis con survivina. |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| AU2003237616B2 (en) * | 2002-01-17 | 2007-07-05 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| NZ538288A (en) | 2002-08-21 | 2008-04-30 | Univ British Columbia | Treatment of melanoma by reduction in clusterin levels |
| JP4717633B2 (ja) * | 2002-08-21 | 2011-07-06 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US8061408B2 (en) | 2009-10-13 | 2011-11-22 | Varel Europe S.A.S. | Casting method for matrix drill bits and reamers |
-
2003
- 2003-08-21 NZ NZ538288A patent/NZ538288A/en not_active IP Right Cessation
- 2003-08-21 US US10/646,391 patent/US7285541B2/en not_active Expired - Fee Related
- 2003-08-21 PT PT03792074T patent/PT1530636E/pt unknown
- 2003-08-21 CA CA2494764A patent/CA2494764C/en not_active Expired - Fee Related
- 2003-08-21 SI SI200331891T patent/SI1530636T1/sl unknown
- 2003-08-21 AU AU2003258425A patent/AU2003258425B2/en not_active Ceased
- 2003-08-21 KR KR1020057002964A patent/KR101052289B1/ko not_active Expired - Fee Related
- 2003-08-21 WO PCT/CA2003/001276 patent/WO2004018675A1/en not_active Ceased
- 2003-08-21 DK DK03792074.1T patent/DK1530636T3/da active
- 2003-08-21 DE DE60333839T patent/DE60333839D1/de not_active Expired - Lifetime
- 2003-08-21 JP JP2005501197A patent/JP4620585B2/ja not_active Expired - Fee Related
- 2003-08-21 AT AT03792074T patent/ATE478142T1/de active
- 2003-08-21 EP EP03792074A patent/EP1530636B1/en not_active Expired - Lifetime
-
2005
- 2005-02-02 IL IL166657A patent/IL166657A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051426A patent/NO333254B1/no not_active IP Right Cessation
-
2010
- 2010-11-19 CY CY20101101046T patent/CY1110936T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006502243A (ja) | 2006-01-19 |
| PT1530636E (pt) | 2010-11-17 |
| IL166657A (en) | 2010-05-31 |
| CY1110936T1 (el) | 2015-06-10 |
| US7285541B2 (en) | 2007-10-23 |
| EP1530636A1 (en) | 2005-05-18 |
| DE60333839D1 (de) | 2010-09-30 |
| EP1530636B1 (en) | 2010-08-18 |
| IL166657A0 (en) | 2006-01-15 |
| ATE478142T1 (de) | 2010-09-15 |
| NZ538288A (en) | 2008-04-30 |
| JP4620585B2 (ja) | 2011-01-26 |
| AU2003258425A1 (en) | 2004-03-11 |
| US20040082534A1 (en) | 2004-04-29 |
| CA2494764A1 (en) | 2004-03-04 |
| DK1530636T3 (da) | 2010-11-29 |
| AU2003258425B2 (en) | 2008-02-14 |
| KR101052289B1 (ko) | 2011-07-27 |
| SI1530636T1 (sl) | 2010-12-31 |
| CA2494764C (en) | 2013-04-23 |
| KR20050058425A (ko) | 2005-06-16 |
| NO20051426L (no) | 2005-05-12 |
| WO2004018675A1 (en) | 2004-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110936T1 (el) | Θεραπεια μελανωματος με μειωση των επιπεδων της clusterin | |
| Hwang et al. | A mechanism of low molecular weight fucoidans degraded by enzymatic and acidic hydrolysis for the prevention of UVB damage | |
| BRPI0410886A (pt) | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único | |
| WO2000049937A3 (en) | Trpm-2 antisense therapy | |
| MX2010001535A (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa. | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2003070283A3 (en) | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| BRPI0819719B8 (pt) | compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo | |
| Yang et al. | The role of CDR1as in proliferation and differentiation of human umbilical cord‐derived mesenchymal stem cells | |
| NO20033665D0 (no) | Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer | |
| MX2023011909A (es) | Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso. | |
| NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| MX2025007910A (es) | Conjugados lipidicos para la administracion de agentes terapeuticos al tejido adiposo | |
| WO2010075287A3 (en) | Compounds and methods for the treatment of pain and other diseases | |
| Park et al. | Effects of xanthium stramarium and psoralea corylifolia extracts combined with UVA1 irradiation on the cell proliferation and TGF-β1 expression of keloid fibroblasts | |
| KR102552776B1 (ko) | miRNA를 포함하는 흑색종 전이 억제용 조성물 | |
| WO2007121054A3 (en) | Nucleic acids for apoptosis of cancer cells | |
| AU2606000A (en) | Antisense modulation of x-linked inhibitor of apoptosis expression | |
| WO2006013193A3 (en) | Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors | |
| AU3934000A (en) | Inhibitors of endothelin-1 synthesis | |
| DE60126591D1 (de) | In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB | |
| EP2907874A1 (en) | MiR-21-3p inhibitors in skin disorders | |
| WO2004043406A3 (en) | ENGINEERED RNAi ADENOVIRUS SILENCING EXPRESSION (ERASE) OF DNA REPAIR PROTEINS | |
| BRPI0409980A (pt) | uso de derivados de ácido fenoxiacético para tratar bexiga hiperativa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |